Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on December 11, 2025. The filing addresses a corporate governance event regarding the company's 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statement data.
Material Changes and Events
- Adjournment of Annual Meeting: The 2025 Annual Meeting of Stockholders, originally convened on December 11, 2025, was adjourned.
- New Meeting Date: The meeting has been rescheduled to January 8, 2026, at 10:00 a.m. Eastern Time.
- Reason for Adjournment: The adjournment was necessary to achieve a quorum and to allow additional time to solicit proxies on behalf of the Board of Directors.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or specific risk factors beyond the immediate procedural issue of failing to secure a quorum for the Annual Meeting. The press release regarding this event is furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the proxy solicitation status and the number of shares represented at the rescheduled meeting on January 8, 2026.
- Review the attached press release (Exhibit 99.1) for details on the specific proposals to be voted on.
- Confirm the continued status of James Parslow as Interim Chief Executive Officer and Chief Financial Officer.